Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones

Jemal, 2005, Cancer statistics, 2005, CA Cancer J Clin, 55, 10, 10.3322/canjclin.55.1.10

Esteva, 2001, Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond, The Oncologist, 6, 133, 10.1634/theoncologist.6-2-133

Choy, 1999, Taxanes in combined-modality therapy for solid tumors, Oncology (Williston Park), 13, 23

Goodin, 2004, Epothilones: Mechanism of action and biologic activity, J Clin Oncol, 22, 2015, 10.1200/JCO.2004.12.001

Bollag, 1995, Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action, Cancer Res, 55, 2325

Kar, 2003, Repeat motifs of tau bind to the insides of microtubules in the absence of taxol, EMBO J, 22, 70, 10.1093/emboj/cdg001

Nettles, 2004, The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography, Science, 305, 866, 10.1126/science.1099190

Bode, 2002, Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules, Biochemistry, 41, 3870, 10.1021/bi0121611

Chou, 1998, Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B, Proc Natl Acad Sci U S A, 95, 9642, 10.1073/pnas.95.16.9642

Kowalski, 1997, Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)), J Biol Chem, 272, 2534, 10.1074/jbc.272.4.2534

Nicolaou, 1997, Synthesis of epothilones A and B in solid and solution phase, Nature, 387, 268, 10.1038/387268a0

Wartmann, 2002, The biology and medicinal chemistry of epothilones, Curr Med Chem Anticancer Agents, 2, 123, 10.2174/1568011023354489

Lee, 2001, BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy, Clin Cancer Res, 7, 1429

Schinkel, 1997, The physiological function of drug-transporting P-glycoproteins, Semin Cancer Biol, 8, 161, 10.1006/scbi.1997.0068

Altmann, 2000, Epothilones and related structures–a new class of microtubule inhibitors with potent in vivo antitumor activity, Biochim Biophys Acta, 1470, M79

Tanabe, 2005, Interactions of patupilone (epothilone B) with multidrug transporter proteins, Proc Am Assoc Cancer Res, 46, 3430a

Hoffmann, 2005, New synthetic epothilone derivative ZK-EPO inhibits breast cancer metastasis, Proc Am Assoc Cancer Res, 47, 3424a

Chou, 2001, The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice, Proc Natl Acad Sci U S A, 98, 8113, 10.1073/pnas.131153098

Zhou, 2005, KOS-1584: A rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties, Proc Am Assoc Cancer Res, 46, 2535a

Calvert, 2001, A phase I study and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 20, 429a

Rubin, 2005, Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors, J Clin Oncol, 23, 9120, 10.1200/JCO.2005.03.0981

Aisner, 2003, Two phase IB trials of EPO906 plus carboplatin in patients with malignancies, Proc Am Soc Clin Oncol, 22, 143a

Gore, 2005, Phase I trial of patupilone plus carboplatin in patients with advanced cancer, Proc Am Soc Clin Oncol, 24, 5087a, 10.1200/jco.2005.23.16_suppl.5087

Dumez, 2004, Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer, Proc Am Soc Clin Oncol, 23, 2093a, 10.1200/jco.2004.22.90140.2093

O'Shaughnessy, 2002, Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results, J Clin Oncol, 20, 2812, 10.1200/JCO.2002.09.002

Rinehart, 2005, Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer, Proc Am Soc Clin Oncol, 24, 3100a

Wojtowicz, 2004, Phase I dose-escalating trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer, Proc Am Soc Clin Oncol, 23, 4623a, 10.1200/jco.2004.22.90140.4623

Spriggs, 2001, Phase 1 first-in-man study of epothilone B analog BMS-247550 in patients with advanced cancer, Proc Am Soc Clin Oncol, 20, 428a

Gadgeel, 2005, Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design, Clin Cancer Res, 11, 6233, 10.1158/1078-0432.CCR-05-0127

Mani, 2004, Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors, Clin Cancer Res, 10, 1289, 10.1158/1078-0432.CCR-0919-03

Shimizu, 2005, Phase I study of BMS-247550 (Ixabepilone) given every 3 weeks in Japanese patients with refractory solid tumors, Proc Am Soc Clin Oncol, 24, 2050a, 10.1200/jco.2005.23.16_suppl.2050

Abraham, 2003, Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days, J Clin Oncol, 21, 1866, 10.1200/JCO.2003.03.063

Widemann, 2005, Phase I trial of the epothilone BMS-247550 (ixabepilone) in children with refractory solid tumors, Proc Am Soc Clin Oncol, 24, 8529a, 10.1200/jco.2005.23.16_suppl.8529

Zhuang, 2005, A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days, Cancer, 103, 1932, 10.1002/cncr.20977

Awada, 2001, Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors, Proc Am Soc Clin Oncol, 20, 427a

Hao, 2002, Continuous weekly administration of the epothilone-B derivative, BMS-247550 (NSC710428): A phase I and pharmacokinetic (PK) study, Proc Am Soc Clin Oncol, 21, 411a

Burris, 2002, Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies, Proc Am Soc Clin Oncol, 21, 412a

Plummer, 2002, Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies, Proc Am Soc Clin Oncol, 21, 2125a

Thomas, 2003, A phase I trial of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline, Proc San Antonio Breast Cancer Symp, 82, 350a

Anderson, 2004, Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies, Proc Am Soc Clin Oncol, 23, 2098a, 10.1200/jco.2004.22.90140.2098

Low, 2005, Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer, J Clin Oncol, 23, 2726, 10.1200/JCO.2005.10.024

Roche, 2002, Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-naïve or taxane-refractory metastatic breast cancer, Proc Am Soc Clin Oncol, 21, 223a

Llombart, 2005, Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): preliminary efficacy and safety data, Proc Am Soc Clin Oncol, 24, 586a, 10.1200/jco.2005.23.16_suppl.586

Baselga, 2005, Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC), Proc San Antonio Breast Cancer Symp, 94, 305a

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER-2 Positive Metastatic Breast Cancer

Trastuzumab and Ixabepilone in Treating Women With HER-2 Positive Metastatic Breast Cancer

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Mekhail, 2003, Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days, Proc Am Soc Clin Oncol, 22, 515a

Sessa, 2003, Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer, Proc Am Soc Clin Oncol, 22, 519a

Piro, 2003, KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies, Proc Am Soc Clin Oncol, 22, 539a

Spriggs, 2003, KOS-862 (epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies, Proc Am Soc Clin Oncol, 22, 894a

Holen, 2004, Phase I study using continuous intravenous (IC) KOS-862 (Epothilone D) in patients with solid tumors, Proc Am Soc Clin Oncol, 23, 2024a, 10.1200/jco.2004.22.90140.2024

Marshall, 2005, Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors, Proc Am Soc Clin Oncol, 24, 2041a, 10.1200/jco.2005.23.16_suppl.2041

Monk, 2005, Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors, Proc Am Soc Clin Oncol, 24, 2049, 10.1200/jco.2005.23.16_suppl.2049

Cortes, 2006, A phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing malignancies, Proc Am Soc Clin Oncol, 25, 2028a, 10.1200/jco.2006.24.18_suppl.2028

Buzdar, 2005, A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results, Proc San Antonio Breast Cancer Symp, 94, 1087a

Schmid, 2005, A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 24, 2051a, 10.1200/jco.2005.23.16_suppl.2051

Roche, 2003, A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline, Proc Am Soc Clin Oncol, 22, 69a